• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·6699.HK
Share

Angelalign Technology Inc. Stocks

HK$ 75.2Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

HK$ 1.60B

HK$ 75.2
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Angelalign Technology Inc. functions as an investment holding enterprise primarily dedicated to the innovation, production, and distribution of clear aligner solutions for orthodontic treatment throughout China. Their key offerings, Angel Aligner Pro and Angel Aligner Classic, are bespoke, removable clear aligners designed to gradually guide a patient's teeth into proper alignment over time. Beyond aligner development, the company also operates dental clinics that provide a variety of services, including orthodontics and cosmetic dentistry, and distributes intraoral scanners. Their extensive portfolio of clear aligner brands features Angelalign, Angelalign Pro, Angelalign Kid, and COMFOS. The firm was founded in 2003 and maintains its principal offices in Shanghai, China.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair va

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 6699.HK is 97.1 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 07:30

Chinese AI developer DeepSeek has begun preparations for an IPO next year — Bloomberg

15.07.2026 03:24

Lucid's stock plummeted following news of a possible bankruptcy. At one point, it was down 57%.

15.07.2026 02:16

"The Prisoner's Dilemma": JPMorgan Warns of a Threat to Coinbase and Circle's Profits

15.07.2026 01:24

Inflation data pushed the indices higher. Software developers are under pressure again

15.07.2026 00:57

Biogen shares fell after disappointing data on its Alzheimer's drug

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026